Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
about
Beta class II tubulin predominates in normal and tumor breast tissues.No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatinClass III β-tubulin counteracts the ability of paclitaxel to inhibit cell migrationNew insights into mechanisms of resistance to microtubule inhibitorsModulation of paclitaxel resistance by annexin IV in human cancer cell linesRole of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate CancerPreclinical discovery of ixabepilone, a highly active antineoplastic agentModulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cellsPaclitaxel resistance in untransformed human mammary epithelial cells is associated with an aneuploidy-prone phenotype.Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancerMechanisms of Taxol resistance related to microtubules.Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy.Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes.Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells.βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancerClass III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology.Polymer genomics: an insight into pharmacology and toxicology of nanomedicinesExpression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane.Altered TUBB3 expression contributes to the epothilone response of mitotic cells.Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to TaxolBlockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells.Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitorsPaclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes.Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burdenAlteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85.Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.Docetaxel in the treatment of advanced non-small-cell lung cancer.Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids.Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxelMicrotubule targeting agents: from biophysics to proteomics.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?Tubulin: an example of targeted chemotherapy.Apoptosis and molecular targeting therapy in cancer.Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins.Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status.The Elephant in the Room: The Role of Microtubules in Cancer.
P2860
Q21195178-1FA34F1B-FE7C-458E-BDC0-9913EE312791Q24531843-6023AC57-87D5-432B-9C8B-73968884548BQ24617268-2F75B652-763D-4FAA-8FA1-8CB359C20316Q24633853-C93E9BEF-D64F-40AD-9070-518270C501ABQ24644209-1FC60588-15C1-4947-AADB-22CDFB11CD00Q28075965-F5E22E9E-EF0A-4097-AA07-6DF613AB987CQ28272975-6DC03344-78C3-4446-83F9-244267B364ACQ28348244-C55E07E2-1E82-4F67-A685-DB4E1A2A1E3CQ30438626-DE1039DE-DC02-460F-A164-3623BD5A9BDEQ31152523-01A15DEE-9886-45FF-96A8-6386407E92BEQ33589802-8653C670-9A8C-48A0-9079-38048E2317D4Q33688044-1031179D-8DBF-428A-BDE0-E6BB4A3A94B5Q33903541-629A33F0-2A77-4128-AD35-6E1AEF5F33F2Q34203414-ABCE9313-A76D-406F-A939-EE32727A525DQ34428153-456C8C00-729A-40A1-A04A-23D5E03DB351Q34958852-FABA94A4-297F-469F-AB15-7BF619058C22Q35220218-8CF08E52-5E6B-4245-9A4F-A7E929F3914EQ35273536-5FE0D004-59F0-4830-8ECB-5FE4A9777AEEQ35634946-40F4E21D-CA4C-443E-AC65-35ED99BD170DQ35754353-2DCC9E17-F97F-4EBF-8ADD-6387C5B974F2Q36244183-C919C687-BA79-4E3A-8A27-56FBE54D9994Q36557893-B83CB807-4A76-4BF4-B1F9-813DCE8FBB65Q36620261-4229B515-AD62-4100-A7E0-849406681B48Q36620293-707706EC-BF9D-40FA-BCB7-BF9012E60542Q36621623-B3E9B997-8A3C-4D72-8254-438ABBE79C6CQ36832450-C9E37DF5-6FB3-4201-B47B-BDDA865BF07DQ36891437-BE0F9F5B-CB4C-4725-BDBC-1B879F0490AEQ36935223-7CDF11C0-4DAF-4F76-A598-ECDBAC1DEE34Q37038455-EA1BE334-5714-4C0C-A907-63A2664C6C5CQ37242661-A97BA058-F1D6-4D40-9485-EFB30E637C8CQ37447324-6D334102-ECDD-447D-A832-C67F57447441Q37625835-2E0B97C8-B57E-4FC9-9C47-11F6A8C0B937Q37682659-538B03ED-C343-4752-9469-16912559BBE6Q38030053-2195DF78-40D5-40BC-ADFE-4BDC03DEF589Q38069185-210B272C-41FE-4977-8411-1F497E4ED26FQ38086872-20530310-0567-4040-BB6E-3C83B62B67F5Q38228349-302C4C39-D99A-4A46-9198-DECD4D3A3046Q38305006-3A81C229-0CD6-44F2-9C39-808293309BC3Q38457106-152E507F-66F9-4BC2-89C0-E85C922B7CEFQ38672574-991C201A-0523-4B27-BE91-B3CD7B283126
P2860
Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Altered beta-tubulin isotype e ...... human prostate carcinoma cells
@ast
Altered beta-tubulin isotype e ...... human prostate carcinoma cells
@en
type
label
Altered beta-tubulin isotype e ...... human prostate carcinoma cells
@ast
Altered beta-tubulin isotype e ...... human prostate carcinoma cells
@en
prefLabel
Altered beta-tubulin isotype e ...... human prostate carcinoma cells
@ast
Altered beta-tubulin isotype e ...... human prostate carcinoma cells
@en
P2093
P2860
P356
P1476
Altered beta-tubulin isotype e ...... human prostate carcinoma cells
@en
P2093
C A Benetatos
D W Dexter
P J Colarusso
S Ranganathan
P2860
P2888
P304
P356
10.1038/BJC.1998.91
P407
P577
1998-02-01T00:00:00Z
P5875
P6179
1016001618